Table 1.
Patients’ demographics and outcomes from the included randomised controlled trials
| Name of the study | PIONEER AF-PCI*11 | RE-DUAL PCI12 | AUGUSTUS*13 | ENTRUST AF-PCI14 | ||||
| Relevant groups in the study | DAT | TAT | DAT | TAT | DAT | TAT | DAT | TAT |
| Rivaroxaban +P2Y12i |
VKA +P2Y12i+ASA |
Dabigatran +P2Y12i |
VKA +P2Y12i+ASA |
Apixaban +P2Y12i |
VKA +P2Y12i+ASA |
Edoxaban +P2Y12i |
VKA +P2Y12i+ASA |
|
| n | 696 | 697 | 1744 | 981 | 1143 | 1123 | 751 | 755 |
| Baseline characteristics | ||||||||
| Age (years, SD or IQR) | 70.4 (9.1) | 69.9 (8.7) | 70.2 (8.4) | 71.7 (8.9) | 70.6 (64–77) | 70.8 (64–77) | 69 (63–77) | 70 (64–77) |
| Female (%) | 25.50 | 26.60 | 24.30 | 23.50 | 27.80 | 30.20 | 26.00 | 25.40 |
| Risk factors | ||||||||
| Diabetes (%) | 28.80 | 31.30 | 35.70 | 37.90 | 36.20 | 36.50 | 34.50 | 34.20 |
| Hypertension (%) | 73.30 | 75.40 | NR | NR | 88.50 | 88.00 | 90.00 | 91.00 |
| Dyslipidaemia (%) | 42.60 | 44.80 | NR | NR | NR | NR | 66.20 | 64.10 |
| History of MI (%) | 19.80 | 22.20 | 24.70 | 27.30 | NR | NR | 25.00 | 23.40 |
| Type of index event (%) | ||||||||
| ACS | 51.50 | 52.20 | 51.60 | 48.40 | 61.70 | 60.70 | 51.70 | 51.50 |
| Non-ACS | 48.50 | 47.80 | 48.40 | 51.60 | 38.30 | 39.30 | 48.30 | 48.50 |
| Outcomes | ||||||||
| Major or CRNM bleeding (ISTH) (%) | 16.80 | 25.50 | 17 | 27 | 7.30 | 18.70 | 17 | 20 |
| Death from any cause (%) | 2.30 | 1.90 | 4.90 | 4.90 | 3.40 | 2.90 | 6.10 | 4.90 |
| MI (%) | 3.00 | 3.50 | 4.00 | 3.00 | 3.30 | 2.90 | 3.90 | 3.00 |
| Stroke (%) | 1.30 | 1.20 | 1.50 | 1.30 | 0.40 | 1.00 | 1.30 | 1.60 |
| Stent thrombosis (%) | 0.80 | 0.70 | 1.30 | 0.80 | 1.80 | 1.00 | 1.70 | 1.30 |
*The patients’ baseline characteristics for these studies are based on the overall population in the studies.
ACS, acute coronary syndrome; AF, atrial fibrillation; ASA, aspirin; CRNM, clinically relevant non-major; DAT, dual antithrombotic therapy; ISTH, International Society on Thrombosis and Haemostasis; MI, myocardial infarction; NR, not reported; PCI, percutaneous coronary intervention; P2Y12 i, P2Y12 inhibitors; TAT, triple antithrombotic therapy; VKA, vitamin K antagonist.